Recently, for ALK-rearranged NSCLC patients, the CROWN trial demonstrated that lorlatinib attributes to a relatively lower hazard ratio of disease progression in non-Asian subjects (HR:0.19, CI: 0.11–0.32) than in Asian subjects (HR:0.47, CI: 0.27–0.82) [13]. Here, ALK is linked to non-small cell lung carcinoma.